Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 • 10,605 citations

Evaluation of survival data and two new rank order statistics arising in its consideration.

1966 • 7,595 citations

Microtubule-Associated Proteins

1986 • 559 citations

Regulation of microtubule dynamics by cdc2 protein kinase in cell-free extracts of Xenopus eggs

1990 • 446 citations

Clinical Epidemiology and Biostatistics

1988 • 338 citations

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

1985 • 267 citations

Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer

1992 • 206 citations

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1985 • 172 citations

Prognostic Significance of Prostate Specific Antigen in Endocrine Treatment for Prostatic Cancer

1990 • 124 citations

Proteins of the mammalian mitotic spindle: phosphorylation/dephosphorylation of MAP-4 during mitosis

1991 • 121 citations

Estramustine‐induced mitotic arrest in two human prostatic carcinoma cell lines du 145 and PC‐3

1984 • 117 citations

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

1983 • 86 citations

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.

1988 • 77 citations

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

1990 • 72 citations

Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the Prostate

1981 • 71 citations

Interaction of estramustine phosphate with microtubule‐associated proteins

1985 • 70 citations

Estramustine binds map-2 to inhibit microtubule assembly in vitro

1988 • 69 citations

A Comparison of Estramustine Phosphate Versus Cis-platinum Alone Versus Estramustine Phosphate Plus Cis-platinum in Patients with Advanced Hormone Refractory Prostate Cancer Who Had Had Extensive Irradiation to the Pelvis or Lumbosacral Area

1983 • 61 citations

Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine

1987 • 58 citations

Antimicrotubule effects of estramustine, an antiprostatic tumor drug.

1985 • 58 citations

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.

1985 • 51 citations

Treatment of Advanced Carcinoma of the Prostate with Estramustine Phosphate

1977 • 43 citations

Prostate Specific Antigen for Assessing Response to Ketoconazole and Prednisone in Patients with Hormone Refractory Metastatic Prostate Cancer

1990 • 35 citations

The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.

1991 • 28 citations

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype

1991 • 22 citations

Carbamate ester latentiation of physiologically active amines

1970 • 22 citations